Efficacy and safety of Radix Astragali in the treatment of hypoxic ischemic encephalopathy in newborns:Meta-analysis
Author(s): YANG Chun-song, LIU Yun-zhu, ZHANG Si-si, YANG Ya-ya, SHEN Hong-xin, ZHANG Ling-li, Department of Pharmacy, Evidence-based Pharmacy Center, West China second hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University
Pages: 639-645
Year: 2016 Issue: 4
Journal: International Journal of Pharmaceutical Research
Keyword: Radix Astragali; hypoxic ischemic encephalopathy; newborns; Meta-analysis;
Abstract: Objective To evaluate the efficacy and safety of Radix Astragali(Huang Qi)for newborns with hypoxic ischemic encephalopathy(HIE). Methods We searched the Cochrane library,Pub Med,Cochrane,EMBASE,CBM,CNKI,VIP and Wanfang database,randomized controlled trial(RCT)evaluating the efficacy and safety of Huang Qi for newborns with HIE would be included and the methodological quality of RCT was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. Results Thirteen studies were included(1031 patients),11 RCT used open control as control,2 RCT used positive control. There was no trial reported the death or disability at the end of 12 months follow-up period. Meta-analysis of one study showed Huang Qi group could not significantly reduced mortality rate of HIE compared with open control group[RR=0.33,95%CI(0.04,3.07)]. Meta analysis of 7 studies(n=597)showed that the efficacy rate of huang Qi group was significantly higher than that of open control group in treatment of HIE[RR=1.22,95%CI(1.07,1.39),I2=48%]. Meta-analysis of 3 trials(n=163)showed that there was significant difference in the improvement of NANA scale on the seventh day[MD=5.37,95%CI(1.46,9.27),I2=89%]between Huang Qi group and open control group. Meta-analysis of 2 trials(n=111)showed that there was significant difference in the improvement of NANA scale on the tenth day[MD=2.03,95%CI(1.37,2.69),I2=0]between Huang Qi group and open control group.No fatal side effects were reported. Conclusion Based on the current evidence,due to the limitation of quality of included studies and sample size,the routine use of Huang Qi for treatment of HIE in newborns is not recommended. The long-term efficacy and safety studies are required to confirm it.
Pages: 639-645
Year: 2016 Issue: 4
Journal: International Journal of Pharmaceutical Research
Keyword: Radix Astragali; hypoxic ischemic encephalopathy; newborns; Meta-analysis;
Abstract: Objective To evaluate the efficacy and safety of Radix Astragali(Huang Qi)for newborns with hypoxic ischemic encephalopathy(HIE). Methods We searched the Cochrane library,Pub Med,Cochrane,EMBASE,CBM,CNKI,VIP and Wanfang database,randomized controlled trial(RCT)evaluating the efficacy and safety of Huang Qi for newborns with HIE would be included and the methodological quality of RCT was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. Results Thirteen studies were included(1031 patients),11 RCT used open control as control,2 RCT used positive control. There was no trial reported the death or disability at the end of 12 months follow-up period. Meta-analysis of one study showed Huang Qi group could not significantly reduced mortality rate of HIE compared with open control group[RR=0.33,95%CI(0.04,3.07)]. Meta analysis of 7 studies(n=597)showed that the efficacy rate of huang Qi group was significantly higher than that of open control group in treatment of HIE[RR=1.22,95%CI(1.07,1.39),I2=48%]. Meta-analysis of 3 trials(n=163)showed that there was significant difference in the improvement of NANA scale on the seventh day[MD=5.37,95%CI(1.46,9.27),I2=89%]between Huang Qi group and open control group. Meta-analysis of 2 trials(n=111)showed that there was significant difference in the improvement of NANA scale on the tenth day[MD=2.03,95%CI(1.37,2.69),I2=0]between Huang Qi group and open control group.No fatal side effects were reported. Conclusion Based on the current evidence,due to the limitation of quality of included studies and sample size,the routine use of Huang Qi for treatment of HIE in newborns is not recommended. The long-term efficacy and safety studies are required to confirm it.
Related Articles